PURPOSE: Survival of patients with surgically unresectable hepatocellular carcinoma (HCC) is very poor due to the limited effective treatments available. Transhepatic arterial chemoembolization (TACE) and microsphere embolization may offer hope for such patients; however, to date, their efficacy has not been evaluated. This study was designed to compare the effectiveness of these two treatments for patients with unresectable HCC. METHODS: This meta-analysis searched literature using various databases and revealed 13 studies on surgically unresectable HCC patients treated with TACE or microsphere embolization. Response rate, 1-year survival, overall survival, and time to progression were then analyzed and compared. RESULTS: These thirteen studies included 597 and 1,233 patients with unresectable HCC for microsphere embolization and chemoembolization treatments, respectively. The data showed that microsphere embolization therapy was significantly better for longer overall survival, 1-year survival, longer time to progression, and complete or partial response rate than that of chemoembolization treatment. CONCLUSIONS: These data demonstrated that microsphere embolization treatment of patients with surgically unresectable HCC provided much better survival and treatment response than that of TACE.
PURPOSE: Survival of patients with surgically unresectable hepatocellular carcinoma (HCC) is very poor due to the limited effective treatments available. Transhepatic arterial chemoembolization (TACE) and microsphere embolization may offer hope for such patients; however, to date, their efficacy has not been evaluated. This study was designed to compare the effectiveness of these two treatments for patients with unresectable HCC. METHODS: This meta-analysis searched literature using various databases and revealed 13 studies on surgically unresectable HCC patients treated with TACE or microsphere embolization. Response rate, 1-year survival, overall survival, and time to progression were then analyzed and compared. RESULTS: These thirteen studies included 597 and 1,233 patients with unresectable HCC for microsphere embolization and chemoembolization treatments, respectively. The data showed that microsphere embolization therapy was significantly better for longer overall survival, 1-year survival, longer time to progression, and complete or partial response rate than that of chemoembolization treatment. CONCLUSIONS: These data demonstrated that microsphere embolization treatment of patients with surgically unresectable HCC provided much better survival and treatment response than that of TACE.
Authors: Kent Sato; Robert J Lewandowski; James T Bui; Reed Omary; Russell D Hunter; Laura Kulik; Mary Mulcahy; David Liu; Howard Chrisman; Scott Resnick; Albert A Nemcek; Robert Vogelzang; Riad Salem Journal: Cardiovasc Intervent Radiol Date: 2006 Jul-Aug Impact factor: 2.740
Authors: Riad Salem; Robert J Lewandowski; Laura Kulik; Edward Wang; Ahsun Riaz; Robert K Ryu; Kent T Sato; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Saad M Ibrahim; Seanthan Senthilnathan; Talia Baker; Vanessa L Gates; Bassel Atassi; Steven Newman; Khairuddin Memon; Richard Chen; Robert L Vogelzang; Albert A Nemcek; Scott A Resnick; Howard B Chrisman; James Carr; Reed A Omary; Michael Abecassis; Al B Benson; Mary F Mulcahy Journal: Gastroenterology Date: 2010-10-30 Impact factor: 22.682
Authors: Jason T Heckman; Michael B Devera; J Wallis Marsh; Paulo Fontes; Nikhil B Amesur; Shane E Holloway; Michael Nalesnik; David A Geller; Jennifer L Steel; T Clark Gamblin Journal: Ann Surg Oncol Date: 2008-08-12 Impact factor: 5.344
Authors: Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem Journal: Hepatology Date: 2008-01 Impact factor: 17.425
Authors: Arthur J A T Braat; Julia E Huijbregts; I Quintus Molenaar; Inne H M Borel Rinkes; Maurice A A J van den Bosch; Marnix G E H Lam Journal: Front Oncol Date: 2014-07-30 Impact factor: 6.244